Steven G Chrysant

Summary

Publications

  1. ncbi request reprint Has the role of calcium channel blockers in treating hypertension finally been defined?
    George S Chrysant
    Oklahoma Cardiovascular and Hypertension Center, and the University of Oklahoma College of Medicine, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132 4904, USA
    Curr Hypertens Rep 5:295-300. 2003
  2. ncbi request reprint Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis
    Steven G Chrysant
    University of Oklahoma, Oklahoma City, OK 73132, USA
    Curr Med Res Opin 24:1039-47. 2008
  3. ncbi request reprint Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD
    Steven G Chrysant
    Department of Cardiology, University of Oklahoma College of Medicine, 5700 Mistletoe Court, Oklahoma City, OK 73142, USA 1 405 721 6662 1 405 721 8417
    Expert Rev Cardiovasc Ther 11:1115-24. 2013
  4. doi request reprint Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension
    Steven G Chrysant
    University of Oklahoma College of Medicine, 5700 Mistletoe Court, Oklahoma City, OK, 73142, USA
    Curr Hypertens Rep 15:475-83. 2013
  5. pmc Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center at the Christ Hospital, Cincinnati, OH, USA
    Cardiovasc Diabetol 11:134. 2012
  6. doi request reprint An update on the cardiovascular pleiotropic effects of milk and milk products
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, The University of Oklahoma, Oklahoma City, OK 73132, USA
    J Clin Hypertens (Greenwich) 15:503-10. 2013
  7. doi request reprint New insights into the true nature of the obesity paradox and the lower cardiovascular risk
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, OK 73132, USA
    J Am Soc Hypertens 7:85-94. 2013
  8. doi request reprint Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK 73132, USA
    Am J Cardiovasc Drugs 12:375-89. 2012
  9. ncbi request reprint The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, OK, USA
    J Clin Hypertens (Greenwich) 14:644-9. 2012
  10. doi request reprint Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma College of Medicine, Oklahoma City, OK, USA
    Am J Cardiovasc Drugs 12:233-43. 2012

Detail Information

Publications71

  1. ncbi request reprint Has the role of calcium channel blockers in treating hypertension finally been defined?
    George S Chrysant
    Oklahoma Cardiovascular and Hypertension Center, and the University of Oklahoma College of Medicine, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132 4904, USA
    Curr Hypertens Rep 5:295-300. 2003
    ..They can also be used as first-line therapy for older, stroke-prone hypertensive patients. In addition, when a calcium channel blocker is indicated for better blood pressure control, its use should not be withheld for safety concerns...
  2. ncbi request reprint Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis
    Steven G Chrysant
    University of Oklahoma, Oklahoma City, OK 73132, USA
    Curr Med Res Opin 24:1039-47. 2008
    ..Here we report the results of a pre-planned 6-month interim analysis of a long-term, open-label study examining the safety, tolerability and efficacy of the aliskiren/valsartan 300/320-mg combination in patients with hypertension...
  3. ncbi request reprint Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD
    Steven G Chrysant
    Department of Cardiology, University of Oklahoma College of Medicine, 5700 Mistletoe Court, Oklahoma City, OK 73142, USA 1 405 721 6662 1 405 721 8417
    Expert Rev Cardiovasc Ther 11:1115-24. 2013
    ..These drug combinations have been shown to be effective, safe and well tolerated by most patients. ..
  4. doi request reprint Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension
    Steven G Chrysant
    University of Oklahoma College of Medicine, 5700 Mistletoe Court, Oklahoma City, OK, 73142, USA
    Curr Hypertens Rep 15:475-83. 2013
    ....
  5. pmc Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center at the Christ Hospital, Cincinnati, OH, USA
    Cardiovasc Diabetol 11:134. 2012
    ..Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals...
  6. doi request reprint An update on the cardiovascular pleiotropic effects of milk and milk products
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, The University of Oklahoma, Oklahoma City, OK 73132, USA
    J Clin Hypertens (Greenwich) 15:503-10. 2013
    ..The potential beneficial pleiotropic effects from these studies together with collateral literature will be discussed in this review. ..
  7. doi request reprint New insights into the true nature of the obesity paradox and the lower cardiovascular risk
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, OK 73132, USA
    J Am Soc Hypertens 7:85-94. 2013
    ..Therefore, based on recent studies using other indices of body fat distribution, such as WC and WHR, besides BMI, the true existence of OP has been questioned and needs to be confirmed by future studies...
  8. doi request reprint Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK 73132, USA
    Am J Cardiovasc Drugs 12:375-89. 2012
    ....
  9. ncbi request reprint The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, OK, USA
    J Clin Hypertens (Greenwich) 14:644-9. 2012
    ..These beneficial pleiotropic and safe cardiovascular effects of PDE-5 inhibitors will be discussed in this concise review...
  10. doi request reprint Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma College of Medicine, Oklahoma City, OK, USA
    Am J Cardiovasc Drugs 12:233-43. 2012
    ..Although awareness of hypertension in Black patients has increased, blood pressure (BP) is frequently inadequately controlled...
  11. pmc Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma Health and Sciences Center, Oklahoma City, OK, USA
    Drugs R D 12:57-64. 2012
    ..This resistance can be overcome with the combination of ACE inhibitors with diuretics or calcium-channel blockers (CCBs)...
  12. doi request reprint Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College oh Medicine, Oklahoma City, Oklahoma, USA
    Am J Cardiol 109:1681-5. 2012
    ..All these actions are discussed in this concise review. In conclusion, DPP-4 inhibitors are novel antidiabetic agents with pleiotropic cardiovascular protective effects in addition to their antidiabetic action...
  13. doi request reprint The role of angiotensin II receptors in stroke protection
    Steven G Chrysant
    University of Oklahoma College of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, OK 73132, USA
    Curr Hypertens Rep 14:202-8. 2012
    ..In this review, the role of the Ang II receptors and their mechanism of action regarding stroke prevention are discussed in view of the evidence from experimental and clinical studies...
  14. doi request reprint Current status of β-blockers for the treatment of hypertension: an update
    S G Chrysant
    University of Oklahoma, Oklahoma City, OK, USA
    Drugs Today (Barc) 48:353-66. 2012
    ....
  15. doi request reprint Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma College of Medicine, Oklahoma City, OK, USA
    J Am Soc Hypertens 6:132-41. 2012
    ....
  16. ncbi request reprint The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132 4904, USA
    Curr Clin Pharmacol 5:89-95. 2010
    ..This concise review will focus on prevention and the aggressive treatment of the existing cardiovascular risk factors with emphasis on the blockers of RAS, and demonstrate that RAS blockers are the best drugs for its treatment...
  17. doi request reprint Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK, USA
    J Clin Hypertens (Greenwich) 11:475-82. 2009
    ..5 mg/d, and 46.3% for AML+OM+HCTZ 10+40+25 mg/d. Study medication was safe and well tolerated. Combination antihypertensive therapy with AML+OM+/-HTCZ, up-titrated as necessary, allowed a majority of patients to achieve BP goal...
  18. doi request reprint Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension
    Steven G Chrysant
    Clinical Professor, Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, 5850 W Wilshire Blvd, Oklahoma City, OK 73132 4904, USA
    Expert Rev Cardiovasc Ther 7:887-95. 2009
    ..001) and resulted in 54% of patients achieving blood pressure goals. It also decreased the pedal edema induced by amlodipine monotherapy 10 mg/day by 36.1%. This drug combination, besides being effective, is also safe and well tolerated...
  19. doi request reprint Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study
    Steven G Chrysant
    University of Oklahoma, School of Medicine, Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma 73132, USA
    Am J Cardiovasc Drugs 9:241-51. 2009
    ....
  20. ncbi request reprint Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, 5850 W Wilshire Blvd, Oklahoma City, OK 73132, USA
    J Natl Med Assoc 101:300-7. 2009
    ..Fixed-dose irbesartan/HCTZ combination treatment provided effective and well-tolerated BP lowering in a diverse population of patients with isolated systolic hypertension...
  21. doi request reprint Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, Oklahoma, USA
    Clin Ther 30:2181-90. 2008
    ..Initiation of treatment, at any stage in its course, might prevent or delay its further progression...
  22. doi request reprint Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema
    Steven G Chrysant
    University of Oklahoma and the Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK, USA
    J Clin Hypertens (Greenwich) 10:716-22. 2008
    ..The incidence of dihydropyridine CCB-induced edema appears to be dependent on the method of edema assessment...
  23. ncbi request reprint Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases
    Steven G Chrysant
    University of Oklahoma, Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132 4904, USA
    Curr Clin Pharmacol 1:139-46. 2006
    ..All these actions of the ARBs will be discussed in this comprehensive review...
  24. ncbi request reprint Using fixed-dose combination therapies to achieve blood pressure goals
    Steven G Chrysant
    University of Oklahoma College of Medicine, Oklahoma Cardiovascular Hypertension Center, Oklahoma City, Oklahoma 73132 4904, USA
    Clin Drug Investig 28:713-34. 2008
    ..This approach would improve BP control rates in the US and worldwide...
  25. pmc Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
    S G Chrysant
    Department of Cardiology and Hypertension, Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, OK, USA
    J Hum Hypertens 24:730-8. 2010
    ..These results suggest that the combination of amlodipine+olmesartan medoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations...
  26. doi request reprint Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma, Oklahoma City, Oklahoma, USA
    Am J Cardiol 105:849-52. 2010
    ....
  27. doi request reprint Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination
    S G Chrysant
    The Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma, USA
    Drugs Today (Barc) 47:197-206. 2011
    ..These studies with collateral literature will be discussed in this concise review...
  28. doi request reprint Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132, USA
    Postgrad Med 123:21-31. 2011
    ..In patients with essential HTN for whom dual therapy is inadequate, single-pill triple-drug therapy can offer a simplified and effective treatment strategy...
  29. doi request reprint Current status of aggressive blood glucose and blood pressure control in diabetic hypertensive subjects
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, Oklahoma, USA
    Am J Cardiol 107:1856-61. 2011
    ..In conclusion, a review of recent research findings suggests less aggressive control of glucose and BP, and "the lower the better" may not be defensible at present, until new data become available...
  30. doi request reprint Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension
    Steven G Chrysant
    University of Oklahoma, Oklahoma City, OK, USA
    Curr Med Res Opin 26:2841-9. 2010
    ..To assess the long-term safety and antihypertensive efficacy of aliskiren/valsartan 300/320 mg combination...
  31. doi request reprint Current evidence on the hemodynamic and blood pressure effects of isometric exercise in normotensive and hypertensive persons
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, OK 73132 4904, USA
    J Clin Hypertens (Greenwich) 12:721-6. 2010
    ..Based on these changes, the authors believe that isometric exercise, whether alone or in combination with dynamic exercise, should be recommended to hypertensive patients and be part of a comprehensive treatment regimen...
  32. doi request reprint The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, Oklahoma, USA
    Am J Cardiovasc Drugs 10:315-20. 2010
    ..A MEDLINE search of the English literature from 2006 to 2009 of amlodipine in combination with ARBs revealed six publications, which are included in this review...
  33. doi request reprint Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, Oklahoma, USA
    Am J Cardiol 106:825-9. 2010
    ..In conclusion, most of the reviewed publications suggest a J-curve effect with low diastolic and systolic BP for cardiovascular disease complications but not stroke complications...
  34. doi request reprint Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, Oklahoma, USA
    Clin Drug Investig 30:473-82. 2010
    ..Therefore, it is crucial for an antihypertensive agent to provide a high level of efficacy without compromising tolerability...
  35. doi request reprint The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan
    Steven G Chrysant
    University of Oklahoma and the Oklahoma Cardiovascular and Hypertension Center, 5850 W Eilshire Boulevard, Oklahoma City, OK 73132 4904, USA
    Drugs Today (Barc) 46:151-62. 2010
    ..The combination of aliskiren with valsartan, and with other antihypertensive drugs is discussed...
  36. doi request reprint Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK, USA
    Drugs Today (Barc) 44:443-53. 2008
    ..In addition, due to the metabolic neutrality of both component drugs, these preparations are preferable for the treatment of hypertensive patients with diabetes or the metabolic syndrome, in addition to other cardiovascular risk factors...
  37. ncbi request reprint Current and future status of beta-blockers in the treatment of hypertension
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma 73132 4704, USA
    Clin Cardiol 31:249-52. 2008
    ..There are reservations regarding their administration to diabetic and older hypertensive patients. However, when compelling indications for their use exist, they should not be withheld...
  38. ncbi request reprint The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
    Steven G Chrysant
    Oklahoma Cardiovascular Hypertension Center, Oklahoma City, Oklahoma 73132 4904, USA
    Clin Ther 30:587-604. 2008
    ..Hypertension guidelines recommend the use of 2 agents having complementary mechanisms of action when >1 agent is needed to achieve blood pressure (BP) goals...
  39. ncbi request reprint Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan
    S G Chrysant
    University of Oklahoma, Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132 4904, USA
    J Hum Hypertens 19:173-83. 2005
    ..With respect to the angiotensin receptor blockers, telmisartan has been demonstrated by several studies to be the longest acting among its class of drugs and to effectively prevent the early morning rise of blood pressure...
  40. ncbi request reprint Stroke prevention with losartan in the context of other antihypertensive drugs
    Steven G Chrysant
    University of Oklahoma School of Medicine and Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma 73132, USA
    Drugs Today (Barc) 40:791-801. 2004
    ..These include the prevention of platelet adhesiveness and aggregation and the decrease of serum uric acid levels, which both lead to reduction in cardiovascular and cerebrovascular events. (..
  41. ncbi request reprint Pharmacological and clinical profile of moexipril: a concise review
    Steven G Chrysant
    University of Oklahoma and the Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, USA
    J Clin Pharmacol 44:827-36. 2004
    ..In this review, the pharmacological profile of this drug and its clinical usefulness are discussed...
  42. ncbi request reprint Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, Oklahoma 73132, USA
    Am J Hypertens 17:590-6. 2004
    ....
  43. ncbi request reprint Pharmacological profile and clinical use of moexipril
    Steven G Chrysant
    University of Oklahoma, Oklahoma Cardiovascular and Hypertension Center, 5850 W Wilshire Blvd, Oklahoma City, OK 73132 4904, USA
    Expert Rev Cardiovasc Ther 1:345-52. 2003
    ..In this review, the pharmacological profile of this drug and its clinical usefulness will be discussed...
  44. ncbi request reprint Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT)
    Steven G Chrysant
    University of Oklahoma, Oklahoma Cardiovascular and Hypertension Center, 5850 W Wilshire Blvd, Oklahoma City, OK 73132 4904, USA
    Expert Rev Cardiovasc Ther 1:335-43. 2003
    ..Its fixed combination with hydrochlorothiazide (HCT) is even more effective in controlling blood pressure in 70% of the cases. The most commonly used combinations are valsartan/HCT (Diovan/HCT), 80/12.5 and 160/12.5 mg given once-daily...
  45. ncbi request reprint Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide
    Steven G Chrysant
    University of Oklahoma School of Medicine and Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK, USA
    Expert Opin Pharmacother 5:657-67. 2004
    ....
  46. ncbi request reprint Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    Am J Hypertens 17:252-9. 2004
    ..The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ)...
  47. ncbi request reprint The ALLHAT study: results and clinical implications
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    QJM 96:771-3. 2003
  48. ncbi request reprint Clinical experience with angiotensin receptor blockers with particular reference to valsartan
    Steven G Chrysant
    The University of Oklahoma School of Medicine, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    J Clin Hypertens (Greenwich) 6:445-51. 2004
    ..The role of this system in cardiovascular remodeling and its blockade will be discussed in this review, which will specifically summarize data with the ARB, valsartan...
  49. ncbi request reprint Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132 4904, USA
    J Hum Hypertens 19:923-31. 2005
    ..These include antiplatelet aggregating, hypouricemic, antidiabetic and atrial antifibrillatory effects. However, the most critical factor in stroke prevention is good blood pressure control irrespective of drug used...
  50. ncbi request reprint Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, OK, USA
    J Hum Hypertens 21:699-708. 2007
    ..In addition, the BP lowering effect of olmesartan, like the other members of its class, is greatly enhanced in combination with a diuretic. Its safety profile is similar to the other ARBs and no different than placebo...
  51. ncbi request reprint The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City 73132, USA
    Blood Press Suppl 1:10-7. 2007
    ..This study compared the efficacy and safety of amlodipine/benazepril (10/40 mg/day and 10/20 mg/day) with amlodipine 10 mg/day in patients whose blood pressure (BP) was not adequately controlled with amlodipine monotherapy...
  52. ncbi request reprint The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications
    Steven G Chrysant
    University of Oklahoma School of Medicine and the Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK 73132 4904, USA
    J Clin Hypertens (Greenwich) 9:454-9. 2007
    ..The evidence for this effect of ARBs compared with ACE inhibitors, however, is only indirect. Ongoing clinical trials with head-to-head comparisons of ARBs and ACE inhibitors will hopefully provide the needed information...
  53. ncbi request reprint The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, Oklahoma 73132, USA
    Blood Press Suppl 16:10-7. 2007
    ..CONCLUSION: Amlodipine/benazepril combinations were well tolerated and resulted in significant BP reductions and better BP responder rates than amlodipine monotherapy...
  54. ncbi request reprint Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, 73132 4904, USA
    J Clin Hypertens (Greenwich) 8:493-9; quiz 500-1. 2006
    ..Thus, the long-term treatment of dyslipidemias with these two agents may help to modify risk and reduce cardiovascular morbidity and mortality in these patients over and above benefits achieved by lowering blood pressure...
  55. ncbi request reprint Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension and the University of Oklahoma School of Medicine, Oklahoma City 73132, USA
    Blood Press Monit 11:135-41. 2006
    ..This secondary analysis of a randomized, double-blind study compared the efficacy of olmesartan medoxomil with that of amlodipine besylate in achieving ambulatory blood pressure goals among patients with mild-to-moderate hypertension...
  56. ncbi request reprint The pleiotropic effects of angiotensin receptor blockers
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, OK 73132 4904, USA
    J Clin Hypertens (Greenwich) 8:261-8. 2006
    ..All these actions make the ARBs a true pleiotropic class of drugs. Each of the foregoing effects will be discussed briefly in this concise review...
  57. doi request reprint Aliskiren-hydrochlorothiazide combination for the treatment of hypertension
    Steven G Chrysant
    University of Oklahoma School of Medicine, Oklahoma City, OK 73132 4904 USA
    Expert Rev Cardiovasc Ther 6:305-14. 2008
    ..In this article, the pharmacokinetic and pharmacodynamic profile and the clinical application of aliskiren alone and in combination with HCTZ will be discussed...
  58. ncbi request reprint Fixed low-dose drug combination for the treatment of hypertension
    S G Chrysant
    Department of Medicine, University of Oklahoma, Oklahoma City, USA
    Arch Fam Med 7:370-6. 1998
    ....
  59. ncbi request reprint Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, Oklahoma City, OK 73132 4904, USA
    J Hum Hypertens 17:425-32. 2003
    ....
  60. ncbi request reprint Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and The University of Oklahoma, Oklahoma City, USA
    Am J Hypertens 13:1180-8. 2000
    ..6 v 4.8 +/- 0.9 mm Hg for SDBP, P < .001), but enalapril exerted a similar effect during both diets. Because salt restriction lowered both SSBP and SDBP, the lowest BP achieved with both drugs were during the salt restriction phase...
  61. ncbi request reprint Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, Oklahoma City 73132-4904, USA
    Am J Hypertens 8:418-21. 1995
    ..001). This study demonstrated that the addition of moexipril and verapamil-SR to low dose HCTZ is effective for the treatment of moderate to severe hypertension...
  62. ncbi request reprint Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, Oklahoma City
    Am J Hypertens 2:537-41. 1989
    ..We conclude: (1) the addition of amlodipine to HCTZ enhanced its antihypertensive action; (2) amlodipine was safe and well tolerated; and (3) amlodipine, perhaps, has a favorable effect on lipids...
  63. ncbi request reprint Antihypertensive and metabolic effects of single and combined atenolol regimens
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, The University of Oklahoma, Oklahoma City 73132
    J Clin Pharmacol 32:61-5. 1992
    ..01). Mild, but statistically significant, increases in BUN, glucose, triglycerides, and uric acid were noted in groups 2, 5, and 6 (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)..
  64. ncbi request reprint The current status of angioplasty of atherosclerotic renal artery stenosis for the treatment of hypertension
    Steven G Chrysant
    College of Medicine, University of Oklahoma, Oklahoma City, OK
    J Clin Hypertens (Greenwich) 15:694-8. 2013
    ..For this review, a Medline search of the English literature was conducted from 2006 to 2012, and 13 pertinent studies were selected. These studies with collateral literature will be discussed in this concise review. ..
  65. ncbi request reprint The age-related hemodynamic changes of blood pressure and their impact on the incidence of cardiovascular disease and stroke: new evidence
    Steven G Chrysant
    University of Oklahoma College of Medicine, Oklahoma City, OK
    J Clin Hypertens (Greenwich) 16:87-90. 2014
    ..Accordingly, when treating SBP in the elderly, care should be taken not to lower the DBP below this level in order to minimize the risk for CVD and stoke...
  66. ncbi request reprint Treatment of white coat hypertension
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132 4904, USA
    Curr Hypertens Rep 2:412-7. 2000
    ..In addition, semiannual or annual follow-up with ambulatory blood pressure monitoring is advised...
  67. ncbi request reprint Sustained blood pressure control with controlled-release isradipine
    S G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, Oklahoma City 73132-4904, USA
    Am J Hypertens 8:87-9. 1995
    ..001). The most common clinical side effect was mild ankle edema, which was dose dependent, occurring in 35.5% of the patients taking the 20-mg ICR dose. This study showed that ICR is long acting, effective, and well tolerated...
  68. doi request reprint Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Blood Press Monit 13:21-7. 2008
    ..Both studies support the strategy of using angiotensin receptor blockers with a higher dose of a thazide diuretic (25 mg) for enhancing the control of hypertension...
  69. ncbi request reprint Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
    Alberto Villamil
    Fundapres, Las Heras 2910 Piso 1A, Buenos Aires, Argentina
    J Hypertens 25:217-26. 2007
    ..The effects of these treatments on plasma renin activity (PRA) were also assessed...
  70. ncbi request reprint Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension
    Joel M Neutel
    Orange County Research Center, Tustin, USA
    Hypertens Res 28:555-63. 2005
    ..5 during the last 6 h of the 24-h dosing interval, which corresponds to the high-risk early-morning hours, and that T80/H12.5 provided additional blood pressure reductions...
  71. ncbi request reprint Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial
    Ralph M Vicari
    MIMA Century Research Associates, Melbourne, Florida 32901, USA
    J Am Coll Cardiol 46:1803-11. 2005
    ..This study sought to evaluate the efficacy and safety of fasudil, an orally available rho kinase inhibitor, in patients with stable angina...